The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays

Transfusion

Volumn 44, Issue 3, 2004, Pages 349-358

  Kiely, Philip ^a   Kay, Deborah ^b   Parker, Susan ^b   Piscitelli, Lisa ^b  

^a Australian Red Cross Blood Ser Vic   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C33C ANTIGEN; HEPATITIS C ANTIBODY; NS5 ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ANALYTIC METHOD; ARTICLE; BLOOD DONOR; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; RECOMBINANT IMMUNOBLOT ASSAY; RISK FACTOR; SCREENING; TISSUE DISTRIBUTION;

BLOOD BANKS; BLOOD DONORS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOASSAY; MASS SCREENING; RISK FACTORS; RNA, VIRAL;

EID: 1642339605     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2003.00671.x     Document Type: Article

References (52)

1. Dow BC, Buchanan I, Munro H, et al. Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors. J Med Virol 1996;49:132-6.
2. Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997;26(3 Suppl 1):48s-56s.
3. Tobler LH, Lee SR, Stramer SL, et al. Performance of second- and third-generation RIBAs for confirmation of third-generation HCV EIA-reactive blood donations. Transfusion 2000;40:917-23.
4. Schroter M, Schafer P, Zollner B, et al. Strategies for reliable diagnosis of hepatitis C infection: the need for a serological confirmatory assay. J Med Virol 2001;64:320-4.
5. Kiely P, Wilson D. Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management. Transfusion 2000;40:580-4.
6. Seed C, Margaritis AR, Bolton WV, et al. Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion 2003;43:226-34.
7. Marin MG, Bresciani S, Puoti M, et al. Clinical significance of serum hepatitis C virus (HCV) RNA as a marker of HCV infection. J Clin Microbiol 1994;32:3008-12.
8. Bogard M, Louvet M, Kamalodine T, et al. Detection of hepatitis C viral RNA: comparison of Amplicor single PCR and nested set PCR processes with HCV serology for hemodialyzed patients. Cell Mol Biol 1995;41:725-30.
9. Buffet C, Charnaux N, Laurent-Puig P, et al. Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. J Med Virol 1994;43:259-61.
10. Allain JP, Kitchen A, Aloysius S, et al. Safety and efficacy of hepatitis C virus antibody screening of blood donors with two sequential screening assays. Transfusion 1996;36:401-5.
11. Lemaire JM, Courouce AM, Defer C, et al. HCV RNA in blood donors with isolated reactivities by third-generation RIBA. Transfusion 2000;40:867-70.
12. What are the consequences of indeterminate results in confirmatory tests for antibodies against transmissible viruses? Vox Sang 1997;73:97-104.
13. Wu Y, Schreiber GB, Busch MP, et al. Donor behaviour after notification of abnormal laboratory test results (abstract). Transfusion 1999;39(Suppl):113s.
14. Kleinman SH, Williams AE, Busch MP, Wu Y. Donor reactions to notification of abnormal test results (abstract). Transfusion 1999;39(Suppl):113s.
15. Uyttendaele S, Claeys H, Mertens W, et al. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994;66:122-9.
16. Damen M, Zaaijer HL, Cuypers HT, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995;35:745-9.
17. Busch MP, Tobler LH, Tegtmeier G, et al. Use of third-generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and second-generation recombinant immunoblot assay-indeterminate blood samples: data to support current Food and Drug Administration guidance on HCV lookback. Transfusion 2000;40:10-4.
18. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002;42:966-72.
19. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
20. Busch MP, Conrad A, Gallarda J, et al. Dynamics of HCV viremia during early HCV infection: implications for minipool (MP) vs individual donation (ID) nucleic acid amplification testing (NAT) (abstract). Transfusion 2000;40(Suppl):25s-26s.
21. Nubling CM, Unger G, Chudy M, et al. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002;42:1037-45.
22. Stramer SL, Porter RA, Brodsky JP, et al. Sensitivity of HIV and HCV RNA detection by pooled genome amplification testing (GAT) (abstract). Transfusion 1998;38(Suppl):70S.
23. Busch MP, Rawal BD, Febig EW, et al. Dynamics of HCV viremia and seroconversion in transfusion-acquired HCV infection (abstract). Transfusion 1998;38(Suppl):72s.
24. Busch MP. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda: American Association of Blood Banks; 2001.
25. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis infection. Hepatology 1999;29:908-14.
26. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406.
27. Grant PR, Sims CM, Tedder RS. Quantification of HCV RNA levels and the detection of core antigen in donations before seroconversion. Transfusion 2002;42:1032-6.
28. Hyland C, Seed C, Kiely P, et al. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests. Vox Sang 2003;85:1-8.
29. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion 2000;40:1161-4.
30. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35-46.
31. Pontisso P, Bellati G, Brunetto M, et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999;29:585-9.
32. Yeo AE, Ghany M, Conry-Cantilena C, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepatol 2001;8:256-63.
33. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
34. Courouce AM, Le Marrec N, Girault A, et al. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994;34:790-5.
35. Lefrere JJ, Guiramand S, Lefrere F, et al. Full or partial seroconversion in patients infected by hepatitis C virus. J Infect Dis 1997;175:316-22.
36. Messick K, Sanders JC, Goedert JJ, Eyster ME. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia 2001;7:568-74.
37. Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002;50:693-6.
38. Dow BC, Munro H, Buchanan I, et al. Third-generation recombinant immunoblot assay: comparison of reactivities according to hepatitis C virus genotype. Transfusion 1996;36:547-51.
39. HCV immunoassays and antigen preparations. News and reviews on line. Edn 98.10. Melbourne: National Serology Reference Laboratory, 1998.
40. Kanistanon D, Neelamek M, Dharakul T, Songsivilai S. The immunoreactivity profile of different HCV genotypes on immunoblot assay and its implications in the development of diagnostic assays. Asian Pacific J Allergy Immunol 1997;15:133-40.
41. Halfon P, Bourliere M, Khiri H, et al. Serological response to infection with different isolates of hepatitis C virus. J Viral Hepat 2002;9:438-42.
42. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-8.
43. Psichogiou M, Katsoulidou A, Vaindirli E, et al. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study on Viral Hepatitis. Transfusion 1997;37:858-62.
44. Fang CT, Tobler LH, Haesche C, et al. Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion 2003;43:541-4.
45. Kitchen AD, Tucker NV. The specificity of anti-HCV supplementary assays. Vox Sang 1995;69:100-3.
46. Howell DR, Webster MH, Barbara JA. Retrospective follow-up of recipients and donors of blood donations reactive for anti-HBc or for single HCV antibodies. Transfus Med 2000;10:265-9.
47. Pawlotsky JM, Bastie A, Pellet C, et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996;34:80-3.
48. Tobler LH, Busch MP, Wilber J, et al. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion 1994;34:130-4.
49. Leon P, Lopez JA, Elola C, et al. Detection of antibody to hepatitis C virus E2 recombinant antigen among samples indeterminate for anti-HCV after wide serological testing and correlation with viremia. The Spanish Study Group for Blood Donors at Risk of Transmission of HCV. Vox Sang 1996;70:213-6.
50. Leon P, Lopez JA, Elola C, et al. Use of overlapping synthetic peptides to characterise samples from blood donors with indeterminate results to hepatitis C virus core antigen. Vox Sang 1998;75:32-6.
51. Kiely P, Stewart Y, Castro L. Analysis of voluntary blood donors with biologic false reactivity on chemiluminescent immunoassays and implications for donor management. Transfusion 2003;43:584-90.
52. Wong PY, Dodd R, Kiely P, et al. Characteristics of hepatitis C-positive blood donors in Victoria, Australia. Transfus Med 1999;9:15-9.